Genito-Urinary

Genito-Urinary

We’re here for you. Call us at 844-346-7222 or

find a clinical trial

If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.

16 Clinical Trials
Genito-Urinary Ib/II Pending
nct/study# NCT03869190 / WO39613 - Morpheus Urothelial

Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-based Treatment Combinations In Patients With Urothelial Carcinoma (Morpheus-UC).

Learn More
Genito-Urinary Phase III Accepting Patients
nct/study# NCT03244384 / A031501-JTCC

Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle InvaSive and Locally Advanced Urothelial CaRcinoma (AMBASSADOR) Versus Observation

Learn More
Genito-Urinary Phase II Accepting Patients
nct/study# NCT03117309 / CRN-GU16-260

Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260

Learn More
Genito-Urinary Phase II Accepting Patients
nct/study# NCT04289779 / GU18-343

A Phase 2 Study of CAbozantinib in combination with AtezolizumaB as NeoAdjuvant Treatment for Muscle-Invasive BladdEr Cancer (ABATE)

Learn More
Genito-Urinary Phase II Accepting Patients
nct/study# NCT02625961 / MK-3475-057

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Learn More
Genito-Urinary Phase I/II Accepting Patients
nct/study# NCT02861573 / MK3475-365

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Learn More

We are here for you

For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.